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A B S T R A C T
Background: Short-duration adaptive servo-ventilation (ASV) therapy can be effective for heart
failure (HF) patients. Albuminuria is recognized as a prognostic marker for HF. We investigated
whether short-duration and short-term ASV therapy reduced albuminuria in HF patients.
Methods and results: Twenty-one consecutive HF patients were divided into two groups: those who
tolerated ASV therapy (ASV group, n = 14) and those who did not (non-ASV group, n = 7). ASV
therapy was administered to enrolled patients for 1 week for 2 h per day (1 h in the morning and 1 h
in the afternoon). The urinary albumin to creatinine  ratio (UACR), urinary 24 h norepinephrine (NE)
excretion, high-sensitivity C-reactive protein (hs-CRP), and plasma brain natriuretic peptide (BNP)
levels were measured before and 1 week after ASV therapy. In the ASV group, but not the non-ASV
group, the UACR signiﬁcantly decreased, together with a decrease in urinary NE and hs-CRP levels.
There were signiﬁcant correlations between the changes in UACR and hs-CRP and between the
changes in urinary NE and hs-CRP. Multiple linear regression analyses indicated that ASV use was
the strongest predictor of decreased UACR.
Conclusion: Albuminuria, urinary NE, and hs-CRP levels reduced in HF patients who could receive
short-duration and short-term ASV therapy. Anti-inﬂammatory effects of ASV therapy may partly
mediate the reduction of albuminuria.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Various cardiovascular pathologies are closely associated
with albuminuria, which contributes to the progression of heart
failure (HF). These include activation of the renin–angiotensin
system (RAS) [1], impaired glomerular blood ﬂow [2], systemic
endothelial dysfunction, and vascular inﬂammation [3]. Micro-
albuminuria is a risk and prognostic factor for chronic HF [4,5],
as well as renal failure. In the clinic, the urinary albumin to
creatinine ratio (UACR) is used as a simple and convenient index
to evaluate albuminuria excretion.
We previously showed that adaptive servo-ventilation (ASV)
therapy improved cardiac function and prognosis in HF patients,
and the effects were apparent in HF patients regardless of sleep-
disordered breathing [6]. We further showed that cardiac* Corresponding author at: Department of Cardiovascular and Respiratory
Medicine, Akita University Graduate School of Medicine, Hondoh 1-1-1, Akita
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0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightscontractile dysfunction improved even in patients who used
ASV for a short duration [7]. It is likely that mechanisms underlying
HF improvement with ASV therapy involve reductions in
sympathetic nerve activity as well as hemodynamic assistance.
Elevated sympathetic nerve activity activates the RAS [8],
which can cause vascular inﬂammation and remodeling, where
albuminuria was observed. Moreover, we previously found that
ASV therapy improved renal function through a reduction of
inﬂammatory responses [9]. Based on these ﬁndings, we hypothe-
size that short-duration ASV therapy may reduce albuminuria
in patients with HF.
Methods
Study design
We enrolled 21 consecutive HF patients for ASV therapy from
November 2011 to May 2012 who met the following indications:
(1) diagnosed with New York Heart Association (NYHA) class II or
III stable HF, (2) had left ventricular ejection fraction (LVEF) <55%,
and (3) could receive optimized medical treatment for HF. Patients reserved.
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airway pressure therapy, could not accept conventional drug
therapy, or were admitted 6 months prior to ASV therapy. The
study design is summarized in Fig. 1. Enrolled patients were
divided into two groups based on the results of an ASV mask-
ﬁtting test and a 20 min hemodynamic check during ASV
therapy: patients who tolerated ASV therapy (ASV group, n = 14)
and those who did not (non-ASV group, n = 7). The day after the
ﬁtting tests, patients underwent ASV therapy for 2 h per day: 1 h
in the morning from 10 to 11 AM and 1 h in the afternoon from 2
to 3 PM. Physical examination, echocardiographic parameters,
plasma brain natriuretic peptide (BNP) levels, high sensitivity
C-reactive protein (hs-CRP) levels, 24-h urinary norepinephrine
(NE) excretion levels, 24-h creatinine clearance (CCr), and UACR
were measured before and 1 week after ASV treatment in the
two groups. We evaluated the effects of ASV therapy on
albuminuria in stable chronic HF patients. Therefore, at the
time of the operation of ASV therapy, patients who had just
recovered from acute HF or decompensated HF were excluded
from the study. Prescriptions were not changed during the week
of ASV therapy. All participants provided informed consent prior
to enrollment in the study. This study was approved by the
clinical research and ethics committee of the University of Akita.
Laboratory measurements
Plasma BNP and hs-CRP levels were analyzed from blood
samples using standard methods. Albuminuria was analyzed using
a spot urine sample. Urinary NE excretion and CCr levels were
measured from 24-h urine samples.
Echocardiography
Two-dimensional, M-mode, Doppler echocardiography (iE33;
Philips Medical Systems, Andover, MA, USA) was used to evaluate
various cardiac parameters in the patients. The LVEF, LV end-
systolic volume (LVESV), and LV end-diastolic volume (LVEDV)
were estimated from the apical two- and four-chamber views
using the modiﬁed biplanar Simpson’s rule. The sonographers
were blinded to the study protocol and were not involved in
treating the enrolled patients.
ASV therapy
ASV therapy (AutoSet CS1; ResMed, Sydney, Australia) was
initiated in 21 consecutive patients with HF. During the ﬁrst
20 min of ASV treatment, heart rate (HR), oxygen saturation (SaO2),
and blood pressure were monitored every 5 min. ASV therapy was
initiated by experienced physicians who were familiar with theASV-group
(n = 14)
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Fig. 1. Flow diagram of the study design. HF, heart failure; ASV, adaptive servo-
ventilation.ASV device. An expiratory positive airway pressure of 5 cm H2O
and inspiratory pressure support between 3 and 10 cm H2O were
used. A follow-up assessment was conducted 1 week later.
Compliance data were downloaded from the ASV devices and
checked 1 week after ASV therapy. In addition, physicians who
were familiar with ASV therapy observed and monitored patients
every 20 min during the therapy. Enrolled patients were instructed
to use the ASV device in bed while resting in a supine position,
whether or not they were sleeping.
Statistical analysis
Continuous variables are expressed as means  standard
deviation (SD) except for UACR and BNP data. For continuous
and normally distributed data, Student’s t-test for comparison
between groups or paired t-test for paired sample were used, as
appropriate. For non-normally distributed data, a Wilcoxon signed-
rank test was used for paired sample, and the Mann–Whitney U
test was used when comparing 2 groups. The data of plasma BNP
levels and UACR were natural log-transformed. Categorical
variables were compared using x2 analysis and Yate’s correction.
Correlations were analyzed using Pearson’s correlation coefﬁcient.
All parameters with p < 0.10 on univariate analysis, baseline
ln BNP and age were entered into the multivariate analysis. A
p-value of <0.05 indicated statistical signiﬁcance. All analyses
were performed using the Statistical Package for the Social Science
Windows ver. 16.0 (SPSS, Chicago, IL, USA).
Results
Baseline characteristics of the enrolled HF patients are shown in
Table 1. No signiﬁcant differences in age, gender, body mass index
(BMI), blood pressure, pharmacological data, echocardiographic
parameters, or laboratory data were found between the two
groups. A total of 14 patients used the ASV device for 2 h during the
day (ASV group), while 7 patients could not tolerate ASV therapy
(non-ASV group) due to mask intolerance (n = 5) or subjective
intolerance of positive airway pressure (n = 2). No signiﬁcant
complications were observed during the 1 week of therapy.
Table 2 shows the changes in physical, echocardiographic,
and laboratory data for each group. Echocardiography data
including LVEF and LVEDV were not changed in either group.
There was a signiﬁcant decrease in plasma BNP in the ASV group
[36.8  25.9% (583.4  292.9 to 414.6  584.1 pg/mL)] compared
to the non-ASV group [2.9  39.4% (328.7  209.4 to
311.2  202.6 pg/mL), p = 0.011]. However, there were no differ-
ences in the physical ﬁndings between the groups, including HR,
blood pressure, and BMI.
Fig. 2A depicts the relative change in UACR in patients before
and 1 week after ASV therapy. There are signiﬁcant differences
between the groups [ASV group: 19.6  30.0% (31.5  10.3 to
23.7  10.2 mg/gCr); non-ASV group: 24.8  27.1% (32.1  14.2 to
40.2  17.9 mg/gCr); p = 0.003]. The relative changes in 24-h
urinary NE excretion levels are shown in Fig. 2B. Urinary NE
excretion signiﬁcantly decreased in the ASV group [28.1  22.8%
(219.1  76.6 to 139.9  63.2 mg/day)] compared to the non-ASV
group [1.4  29.5% (204.0  107.2 to 203.6  114.1 mg/day),
p = 0.037]. Fig. 2C shows the change in hs-CRP after therapy. It
also changed signiﬁcantly more in the ASV group [33.4  24.9%
(0.29  0.28 to 0.22  0.25 mg/dL)] than in the non-ASV group
[6.8  45.3% (0.28  0.33 to 0.25  0.31 mg/dL), p = 0.044]. Fig. 2D
shows the relative change in 24-h CCr after therapy. It was
5.5  13.1% (63.8  28.4 to 59.7  26.9 mL/min) in the ASV group
and 0.2  17.7% (58.5  26.1 to 61.4  34.7 mL/min) in the non-
ASV group, although the differences were not statistically
signiﬁcant (p = 0.263).
Table 1
Baseline characteristics of the enrolled HF subjects.
ASV-group Non-ASV-group p-value
N = 14 N = 7
Age (years) 59.6  8.3 67.5  9.4 0.070
Male sex, n (%) 10 (71.4) 4 (57.1) 0.638
BMI (kg/m2) 27.7  4.9 27.6  7.1 0.551
Hypertension, n (%) 8 (57.1) 6 (85.7) 0.337
Diabetes mellitus, n (%) 6 (42.9) 4 (57.1) 0.660
Dyslipidemia, n (%) 7 (50.0) 2 (28.5) 0.642
Underlying heart disease, n (%)
Ischemic heart disease 6 (42.9) 2 (28.5) 0.525
Cardiomyopathy 3 (21.4) 1 (14.3) 0.694
Valvular heart disease 2 (14.3) 2 (28.5) 0.186
Others 3 (21.4) 2 (28.5) 0.717
Heart rhythm disorder, n (%)
Atrial ﬁbrillation 6 (42.9) 3 (42.9) 0.681
Pacing 5 (35.7) 2 (28.6) 0.743
Blood pressure (mmHg)
Systolic 108.5  20.0 110.7  11.2 0.601
Diastolic 57.5  7.4 55.4  7.0 0.389
Medication, n (%)
ACEIs/ARBs 14 (100.0) 7 (100.0) 1.000
b-Blockers 13 (92.8) 6 (85.7) 0.599
Loop diuretics 14 (100.0) 7 (100.0) 1.000
Aldosterone antagonists 12 (85.7) 7 (100.0) 0.293
Statins 11 (78.5) 5 (71.4) 0.717
Ca antagonists 8 (57.1) 4 (57.1) 1.000
Laboratory data
24-h CCr (mL/min) 63.8  28.4 58.5  26.1 0.709
UACR (mg/gCr) 27.4 (24.2–40.1) 25.5 (24.1–44.8) 0.157
Ln UACR 3.31 (3.18–3.68) 3.24 (3.18–3.80) 0.157
Urinary NE (mg/day) 219.1  76.6 204.0  107.2 0.502
Plasma BNP (pg/mL) 430.8 (205.3–829.3) 270.1 (221.0–440.0) 0.502
Ln BNP 6.07 (5.32–6.71) 5.60 (5.39–6.09) 0.502
hs-CRP (mg/dL) 0.29  0.28 0.28  0.33 0.681
Echocardiography data
LVEF (%) 34.5  12.8 38.5  10.3 0.550
LVEDV (mL) 223.7  71.0 202.9  68.0 0.478
LVESV (mL) 154.8  74.3 128.0  58.7 0.455
Values are reported as mean  standard deviation except for UACR, BNP data (median [quartile 1 to quartile 3]). HF, heart failure; ASV, adaptive servo-
ventilation; BMI, body mass index; ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; CCr, creatinine clearance; UACR,
urinary albumin to creatinine ratio; NE, norepinephrine; BNP, brain natriuretic peptide; hs-CRP, high-sensitivity C-reactive protein; LVEF, left ventricular
ejection fraction; LVEDV, left ventricular end diastolic volume; LVESV, left ventricular end systolic volume.
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shown in Fig. 3. The change in UACR was signiﬁcantly correlated
with the change in hs-CRP in the enrolled 21 HF patients (r = 0.726,
R2 = 0.368, p = 0.004). Fig. 4 shows the correlations between theTable 2
Changes of physical, echocardiographic, and laboratory data of enrolled HF patients w
ASV-group (n = 14) 
Before After 1 week 
Physical ﬁndings
Heart rate (/min) 70.2  12.1 67.2  11.0 
Blood pressure
Systolic (mmHg) 108.5  20.0 106.1  16.2 
Diastolic (mmHg) 57.5  7.4 54.4  7.3 
BMI (kg/m2) 26.5  3.4 26.4  2.8 
Echocardiographic data
LVEF (%) 34.5  12.8 35.0  13.7 
LVEDV (mL) 223.7  71.0 216.1  71.9 
LVESV (mL) 154.8  74.3 147.7  76.6 
Laboratory data
24-h CCr (mL/min) 63.8  28.4 59.7  27.0 
UACR (mg/gCr) 31.5  10.3 23.7  10.2 
Urinary NE (mg/day) 219.1  76.6 139.9  63.2 
Plasma BNP (pg/mL) 583.4  292.9 414.6  584.1 
hs-CRP (mg/dL) 0.29  0.28 0.22  0.25 
HF, heart failure; ASV, adaptive servo-ventilation; BMI, body mass index; LVEF, left ve
left ventricular end-systolic volume; CCr, creatinine clearance; UACR, urinary albumin
high-sensitivity C-reactive protein.relative change in urinary NE excretion and hs-CRP in patients with
and without ASV therapy. Signiﬁcant correlations were found
between the two parameters (r = 0.499, R2 = 0.275, p = 0.015).
Moreover, the change in UACR was signiﬁcantly correlated withith or without ASV therapy.
Non-ASV-group (n = 7)
p-value Before After 1 week p-value
ns 61.3  5.5 62.0  4.4 ns
ns 110.7  11.2 114.9  8.6 ns
ns 55.4  7.0 56.1  4.3 ns
ns 25.4  2.3 25.6  1.9 ns
ns 38.5  10.3 37.0  11.8 ns
ns 202.9  68.0 199.6  62.5 ns
ns 128.0  58.7 129.9  60.7 ns
ns 58.5  26.1 61.4  34.7 ns
0.023 32.1  14.2 40.2  17.9 ns
0.005 204.0  107.2 213.6  114.1 ns
0.002 328.7  209.4 311.2  202.6 ns
0.002 0.28  0.33 0.25  0.31 ns
ntricular ejection fraction; LVEDV, left ventricular end-diastolic volume; LVESV,
 to creatinine ratio; NE, norepinephrine; BNP, brain natriuretic peptide; hs-CRP,
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Fig. 2. Relative change in (A) the urinary albumin to creatinine ratio (UACR), (B) urinary norepinephrine (NE), (C) high-sensitivity C-reactive protein (hs-CRP), and (D) 24-h
creatinine clearance (CCr) in heart failure patients with or without ASV therapy. ASV, adaptive servo-ventilation.
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p = 0.029). We conducted multiple linear analyses, including
ASV use, baseline ln BNP, and age, in the enrolled 21 HF patients.
This analysis showed that ASV use was the strongest parameter
indicating reduced UACR (coefﬁcient = 0.694, SE = 6.745,
p = 0.001, Table 3).Relave change of hs -CRP (%)
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Fig. 3. Correlations between a relative change in the urinary albumin to creatinine
ratio (UACR) and high-sensitivity C-reactive protein (hs-CRP) level in heart failure
patients. Black circle = non-ASV group; gray circle = ASV group. ASV, adaptive
servo-ventilation.Discussion
This study demonstrated the effects of short-duration and
short-term ASV therapy on albuminuria in HF patients. We
determined that the UACR, urinary NE excretion, and hs-CRP levels
were signiﬁcantly reduced in the ASV group but not in the non-ASV
group. Signiﬁcant correlations were found between changes in
hs-CRP and UACR. Moreover, the change in hs-CRP was signiﬁ-
cantly correlated with the change in urinary NE and was the
strongest predictor of reduced UACR.Rel ave cha nge of  hs -CR P (%)
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Fig. 4. Correlations between relative changes in norepinephrine (NE) and high-
sensitivity C-reactive protein (hs-CRP) in heart failure patients. Black circle = non-
ASV group; gray circle = ASV group. ASV, adaptive servo-ventilation.
Table 3
Uni- and multivariate linear regression analyses for the reduction of UACR in the enrolled HF patients.
Univariate Multivariate
Coefﬁcient SE p-value Coefﬁcient SE p-value
ASV use 0.603 6.747 0.004 0.694 6.745 0.001
Baseline ln BNP 0.335 8.354 0.093 0.458 6.451 0.049
Age 0.091 0.873 0.695 0.290 0.691 0.228
UACR, urinary albumin to creatinine ratio; HF, heart failure; ASV, adaptive servo-ventilation; SE, standard error; BNP, brain natriuretic peptide.
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lial dysfunction, which may be an important prognostic marker in
patients with HF [3,5]. Serum hs-CRP has been associated with
vascular inﬂammation, and signiﬁcantly correlated with micro-
albuminuria in the general population [3]. One possible cause of
albuminuria in HF patients may be vascular inﬂammation
induced by increased sympathetic nerve activity. Elevated
sympathetic nerve activity activates the RAS system [10], induces
bone marrow inﬂammatory cells [11], and leads to vascular
remodeling events such as vasoconstriction, proliferation of
vascular smooth muscle cells, and vascular inﬂammation. The
present study showed that ASV-mediated changes in hs-CRP
levels were signiﬁcantly correlated with the changes in UACR in
HF patients (Fig. 3), implying that anti-inﬂammatory effects of
ASV therapy may be partly associated with decreased urinary
albumin excretion. In addition, multiple linear regression
analyses showed that ASV use was the strongest parameter
predicting a decrease in UACR (Table 3), which supports the idea
that the polymodal effects of ASV therapy, such as anti-
inﬂammatory effects and hemodynamic support, may contribute
to reduced UACR in HF patients.
ASV therapy has been established as a non-pharmacological
intervention for HF patients with sleep-disordered breathing, such
as central apnea [12,13]. However, abnormal breathing is
frequently observed in HF patients during the daytime [14], which
could enhance sympathetic nerve activity through a reduction in
pulmonary vagal afferents [15]. Because ASV therapy can produce
deep and regular respiratory conditions, it may reduce sympa-
thetic nerve activity. The present study showed that 24-h urinary
NE excretion levels signiﬁcantly decreased in ASV-treated patients
(Fig. 2B). These results conﬁrm that ASV therapy can reduce
sympathetic nerve activity by providing respiratory support.
Elevated sympathetic nerve activity enhances inﬂammation
[16]. Sympathetic activation could directly activate bone marrow
inﬂammatory cells [17] and increase inﬂammatory cytokines, such
as interleukin-6 [18]. In the present study, the relative change in
24-h urinary NE was signiﬁcantly correlated with the change in hs-
CRP levels in the HF patients (Fig. 4), indicating that the reduction
of sympathetic nerve activity by ASV therapy may be associated
with anti-inﬂammatory actions.
We previously showed that short-duration ASV can be an
alternative approach for HF patients who cannot tolerate long-
duration ASV therapy [9]. Hemodynamic improvements by ASV
therapy are produced immediately in HF patients [19]. Yoshihisa
et al. [20] demonstrated that single-night ASV signiﬁcantly
reduced urinary and serum NE levels. In addition, the fact that
the reduction of sympathetic nerve activity, inﬂammation, and
UACR were shown even in short-duration and short-term daytime
ASV therapy provides the rationale for the beneﬁcial effects of
short-duration ASV therapy on HF.
A recent study has shown that improvements in cardiac
function could directly reduce excretion of urinary albumin [21].
The present study provided the result that short-duration and
short-term daytime ASV therapy could reduce plasma BNP levels
together with the reduction in UACR, indicating that hemodynamicsupport provided by ASV therapy could be partly associated with
the reduction in urinary albumin excretion.
There were some limitations to this study due to the
observational study design and small number of patients.
Randomized trials will be needed to clarify the effects of ASV
therapy on albuminuria in HF patients. In this study, because we
could not evaluate 24-h urine test for albumin, the measurement of
urinary albumin may be inaccurate. Furthermore, we did not
demonstrate a direct relationship between RAS inhibition and the
reduction in albuminuria. Finally, we did not assess inﬂammatory
cytokine levels.
In conclusion, urinary albumin, urinary NE excretion, and hs-
CRP levels were reduced in HF patients who could receive short-
duration and short-term ASV therapy, where anti-inﬂammatory
effects of ASV therapy may partly mediate the reduction in
albuminuria.
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